### ðŸ«€ Lipid Management: Icosapent Ethyl for Hypertriglyceridemia in ASCVD

#### âœ… True Statements
1. **Icosapent ethyl**, a highly purified fish oil, may be added in patients with **atherosclerotic cardiovascular disease (ASCVD)** or high cardiovascular risk who have **persistently elevated triglyceride levels** despite statin therapy.
2. Patients at high cardiovascular risk include those **aged â‰¥50 years with diabetes** and **at least one additional ASCVD risk factor**.
3. The **REDUCE-IT trial** demonstrated that **icosapent ethyl** reduced the risk of **cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina** in this population.
4. In REDUCE-IT, **icosapent ethyl** provided a **4.8% absolute risk reduction** in the composite cardiovascular outcome over a **median follow-up of 4.9 years**.
5. **High-intensity statin therapy** is recommended for patients with **diabetes and coronary artery disease (CAD)** to achieve a **â‰¥50% LDL cholesterol reduction** and **LDL cholesterol <55 mg/dL (1.42 mmol/L)**.
6. If LDL cholesterol goals are not achieved with statin monotherapy, **ezetimibe** or **proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors** such as **alirocumab** may be added.
7. **Ezetimibe** and **PCSK9 inhibitors** are not used to lower triglycerides.
8. **Insulin** is not appropriate for lowering triglyceride levels in patients with **adequate glycemic control** (e.g., hemoglobin A1c 6.2%) and may increase the risk of **hypoglycemia**.
9. **Niacin** is no longer recommended in the management of hyperlipidemia due to **lack of benefit on long-term cardiovascular outcomes**, **poor tolerability**, and potential to **worsen glycemic control**.
10. The **American College of Cardiology/American Heart Association (ACC/AHA)** guidelines have excluded **niacin** from recommended lipid-lowering therapy.

#### ðŸ’¬ Extra
1. Icosapent ethyl is appropriate for patients with ASCVD or diabetes and an additional ASCVD risk factor who have triglyceride levels of 135â€“499 mg/dL (1.53â€“5.64 mmol/L) despite statin therapy.
3. The REDUCE-IT trial provides direct evidence for the cardiovascular benefit of icosapent ethyl in this setting.
5. LDL-C goal of <55 mg/dL is based on newer ACC/AHA secondary prevention targets for very high-risk individuals.
6. These agents primarily address LDL-C, not triglycerides.
8. This patientâ€™s hemoglobin A1c of 6.2% indicates good glycemic control without insulin therapy.
9. Niacinâ€™s adverse effects include flushing and worsening insulin resistance.

#### ðŸ“‡ Tags
#Cardiology #Hypertriglyceridemia #IcosapentEthyl #ASCVD #REDUCEIT #Statins #PCSK9Inhibitor #Niacin #LDLCholesterol #Diabetes

#### ðŸ“š Reference
Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11-22. PMID: 30415628 doi:10.1056/NEJMoa1812792

#### ðŸ†” Question ID
CVMCQ24064

#### ðŸ•’ Last Updated
January 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Coronary Artery Disease, Medical Therapy and Secondary Prevention in Patients With Diabetes

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **High-intensity statin therapy** is recommended for all patients with **diabetes and coronary artery disease (CAD)**, regardless of baseline low-density lipoprotein cholesterol (LDL-C).
2. **Ezetimibe** or **PCSK9 inhibitors** should be added if the **LDL-C goal of <70 mg/dL (1.8 mmol/L)** or **<55 mg/dL (1.4 mmol/L)** in patients with prior acute coronary syndrome is not achieved.
3. **Icosapent ethyl** is a reasonable addition for patients with **controlled LDL-C** but **elevated triglyceride levels (135â€“499 mg/dL)** on statin therapy.
4. **Combination therapy** with **statin plus fibrate or niacin** is **not recommended**.
5. **Daily aspirin (75â€“162 mg)** is recommended for **secondary prevention** in patients with **diabetes and CAD**.
6. **Sodium-glucose cotransporter-2 (SGLT2) inhibitors** and/or **glucagon-like peptide-1 (GLP-1) receptor agonists** are recommended in **type 2 diabetes** and **established CAD** to reduce **cardiovascular and renal events**.
7. **Aggressive risk factor reduction**, including **increased physical activity**, **weight loss**, and **glycemic control**, is a foundational component of managing **coronary artery disease (CAD)** in patients with **diabetes**.
8. A **blood pressure target <130/80 mm Hg** is recommended in patients with **diabetes and ASCVD**, provided it can be achieved **without undue treatment burden**.
9. **ACE inhibitors** or **angiotensin receptor blockers (ARBs)** at the **maximally tolerated dose** are the preferred antihypertensives in **diabetes with ASCVD**, due to their **renal and cardiovascular protective effects**.
10. **Î²-Blockers** are indicated in patients with **established coronary artery disease**, though additional antihypertensives may be needed for blood pressure control.
11. The **anticoagulant rivaroxaban (2.5 mg twice daily)** may be combined with **aspirin** in patients with **CAD or peripheral artery disease** and **low bleeding risk** to reduce **major adverse cardiovascular and limb events**.
12. The use of **P2Y12 inhibitors** (such as **clopidogrel** or **ticagrelor**) for **secondary prevention** in patients with **diabetes and CAD** is evolving, with potential benefits offset by **increased bleeding risk**.

#### ðŸ’¬ Extra
1. The goal of LDL-C reduction is â‰¥50% from baseline.
3. Icosapent ethyl is appropriate when triglyceride elevation persists despite statin-based LDL-C control.
4. Lack of outcome benefit and adverse effects limit the use of niacin or fibrates in combination with statins.
6. These agents provide benefit beyond glucose control in patients with diabetes and CAD.
7. Lifestyle interventions complement pharmacologic therapy in diabetes and ASCVD management.
8. This goal aligns with contemporary hypertension guidelines for patients with established cardiovascular disease.
9. ACE inhibitors and ARBs provide dual benefit in protecting both heart and kidneys in high-risk diabetic patients.
10. Î²-blockers improve mortality in CAD, especially postâ€“myocardial infarction, and may be part of a combination antihypertensive regimen.
11. This dual pathway strategy is based on trials like COMPASS, and is selectively used in patients without high bleeding risk.
12. Dual antiplatelet therapy may be considered short-term postâ€“acute coronary syndrome or stenting but requires individualized decision-making.

#### ðŸ·ï¸ Tags
#Statins #IcosapentEthyl #Triglycerides #LDLCholesterol #PCSK9Inhibitor #Ezetimibe #SecondaryPrevention #Diabetes #SGLT2Inhibitor #GLP1ReceptorAgonist #Aspirin #RiskFactorModification #BloodPressure #ACEInhibitor #ARB #BetaBlocker #Rivaroxaban #P2Y12Inhibitor #CAD

---

#### ðŸ§¾ Supplemental Tables

<!-- Antiplatelet Medications Table -->
<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Medication</th>
      <th>Drugs in Class</th>
      <th>Dosage</th>
      <th>Indications</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Aspirin</td>
      <td>N/A</td>
      <td>81-162 mg/d</td>
      <td>All patients with ACS, unless intolerant or allergic. All patients with angina. Aspirin desensitization may be considered for patients with allergy.</td>
      <td>Nonenteric formulation recommended for aspirin-naive patients with ACS.</td>
    </tr>
    <tr>
      <td>Clopidogrel</td>
      <td>N/A</td>
      <td>75 mg/d</td>
      <td>P2Y12 inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year.</td>
      <td>Alternative to aspirin in patients with stable CAD and aspirin allergy.</td>
    </tr>
    <tr>
      <td>Prasugrel</td>
      <td>N/A</td>
      <td>10 mg/d</td>
      <td>P2Y12 inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year; in ACS, only if PCI is performed.</td>
      <td>Contraindicated in age >75 y or history of stroke/TIA; consider 5 mg dose if <60 kg (132 lb).</td>
    </tr>
    <tr>
      <td>Ticagrelor</td>
      <td>N/A</td>
      <td>90 mg twice daily</td>
      <td>P2Y12 inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year.</td>
      <td>Rapid onset; no first-pass metabolism; no known polymorphisms. â†‘ bleeding risk with aspirin â‰¥100 mg.</td>
    </tr>
  </tbody>
</table>

<!-- Cardioprotective Medications Table -->
<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Medication</th>
      <th>Drugs in Class</th>
      <th>Dosage</th>
      <th>Indications</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Î²-Blockers</td>
      <td>Atenolol, metoprolol, carvedilol, nebivolol, bisoprolol</td>
      <td>Variable</td>
      <td>All patients with prior MI or LV systolic dysfunction (only metoprolol succinate, carvedilol, or bisoprolol). Also used for angina.</td>
      <td>Avoid in patients with cardiogenic shock, hypotension, or conduction disturbances.</td>
    </tr>
    <tr>
      <td>ACE inhibitors</td>
      <td>Benazepril, captopril, enalapril, fosinopril, perindopril, trandolapril, lisinopril, ramipril, quinapril</td>
      <td>Variable</td>
      <td>All patients with LV systolic dysfunction, hypertension, diabetes mellitus, or kidney disease.</td>
      <td>Particularly beneficial in patients with anterior MI.</td>
    </tr>
    <tr>
      <td>Angiotensin receptor blockers</td>
      <td>Losartan, valsartan, olmesartan, candesartan, irbesartan, telmisartan</td>
      <td>Variable</td>
      <td>All patients with LV systolic dysfunction, hypertension, diabetes, or kidney disease who are intolerant of ACE inhibitors.</td>
      <td>Should not be used in patients already taking an ACE inhibitor.</td>
    </tr>
    <tr>
      <td>Aldosterone inhibitor</td>
      <td>Eplerenone</td>
      <td>25â€“50 mg/d</td>
      <td>Patients with STEMI who have an LVEF â‰¤40% and either clinical heart failure or diabetes.</td>
      <td>Use with caution in patients with chronic kidney disease or hyperkalemia.</td>
    </tr>
    <tr>
      <td>High-intensity statin therapy</td>
      <td>Atorvastatin, Rosuvastatin</td>
      <td>40â€“80 mg/d, 20â€“40 mg/d</td>
      <td>All patients with evidence of CAD and age â‰¤75 y.</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td>Moderate-intensity statin therapy</td>
      <td>Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin</td>
      <td>10â€“20 mg/d, 5â€“10 mg/d, 20â€“40 mg/d, 40â€“80 mg/d, 40 mg/d, 40 mg twice daily</td>
      <td>All patients with evidence of CAD and age >75 y or otherwise intolerant of high-intensity statin therapy.</td>
      <td>Simvastatin dosage should be limited to 20 mg/d in patients receiving amlodipine.</td>
    </tr>
  </tbody>
</table>

<!-- Antianginal Medications Table -->
<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Medication</th>
      <th>Drugs in Class</th>
      <th>Dosage</th>
      <th>Indications</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Nitroglycerin (sublingual)</td>
      <td>â€”</td>
      <td>0.4 mg every 5 min for up to 3 doses</td>
      <td>Part of multimodal treatment for ongoing chest pain.</td>
      <td>Avoid in SBP <90 mm Hg, bradycardia, RV infarction, PDE-5 inhibitor use in past 24â€“48 h, HCM, or severe AS.</td>
    </tr>
    <tr>
      <td>Nitroglycerin (oral)</td>
      <td>â€”</td>
      <td>Variable</td>
      <td>Angina management.</td>
      <td>Nitrate-free period needed to maintain effectiveness.</td>
    </tr>
    <tr>
      <td>Nitroglycerin (IV)</td>
      <td>â€”</td>
      <td>Initial IV rate 5â€“10 Âµg/min</td>
      <td>Persistent chest pain after 3 SL doses; part of multimodal therapy for heart failure or hypertension.</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td>Dihydropyridine calcium channel blockers</td>
      <td>Amlodipine</td>
      <td>5â€“10 mg/d</td>
      <td>Effective for blood pressure control and angina in patients with persistent hypertension.</td>
      <td>Careful dose titration due to delayed onset of action.</td>
    </tr>
    <tr>
      <td>Nondihydropyridine calcium channel blockers</td>
      <td>Diltiazem, verapamil</td>
      <td>Variable</td>
      <td>Used in NSTE-ACS with refractory angina or Î²-blocker intolerance.</td>
      <td>No benefit in STEMI; avoid in heart failure or conduction abnormalities.</td>
    </tr>
    <tr>
      <td>Ranolazine</td>
      <td>â€”</td>
      <td>500â€“1000 mg twice daily</td>
      <td>Used when unable to tolerate other antianginals due to hypotension or bradycardia. Combine with Î²-blockers, CCBs, or nitrates.</td>
      <td>QT prolongation possible. Dose reduce with moderate CYP3A4 inhibitors. Avoid in cirrhosis or with strong CYP3A4 inhibitors.</td>
    </tr>
  </tbody>
</table>
